Medication info

Olmesartan Medoxomil/Amlodipine Besylate/Hydrochlorothiazide Tablet 5/40/12.5 mg

Prescription medicationTabletOralExpired
Ingredient · strength
Olmesartan Medoxomil›40mg / 1 tabletAmlodipine Besylate›6.944mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
Austin Pharmaceutical Co., Ltd.
Appearance
Pale yellow round film-coated tablet
Packaging
30 tablets/box [10 tablets/Alu-Alu × 3]
Approval status
Expired

MFDS item code 202003535 · Approved 2020.05.15

This product's status changed to Expired on 2025.05.15. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of essential hypertension not controlled with combination therapy
Who takes it
Adults · Children
Adult dose
Take 1 tablet once daily with water, with or without food. If possible, it is recommended that you take it at the same time each day (e.g., in the morning). Before starting this drug, it is recommended that the dose be adjusted using the individual components (olmesartan medoxomil and amlodipine as monotherapy or combination therapy). However, if blood pressure is not controlled with combination therapy of amlodipine and olmesartan medoxomil, switching directly to this drug may be considered as follows. The maximum dose of this drug is 10/40/25mg of amlodipine/olmesartan medoxomil/hydrochlorothiazide. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of 2 weeks or more, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/20mg. - 5/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/40mg or with this drug 5/20/12.5mg. - 5/40/25mg: For patients whose blood pressure is not adequately controlled with this drug 5/40/12.5mg. - 10/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 10/40mg or with this drug 5/40/12.5mg. - 10/40/25mg: For patients whose blood pressure is not adequately controlled with this drug 5/40/25mg or this drug 10/40/12.5mg. ※ Refer to the following dose titration schedule. (The content of each component is listed in the order of amlodipine/olmesartan medoxomil/hydrochlorothiazide.) 5/20/0mg → 5/20/12.5mg ↓ 5/40/0mg → 5/40/12.5mg → 5/40/25mg ↓ ↓ 10/40/0mg → 10/40/12.5mg → 10/40/25mg Patients with renal impairment For patients with mild or moderate renal impairment (creatinine clearance 30-60mL/min), the maximum dose of this drug is 20/5/12.5milligrams once daily. In patients with moderate renal impairment, monitoring of potassium and creatinine levels is recommended. This drug should not be administered to patients with severe renal impairment (creatinine clearance < 30mL/min). Patients with hepatic impairment Caution should be exercised when administering this drug to patients with mild or moderate hepatic impairment. For patients with moderate hepatic impairment, the maximum dose of this drug is 5/20/12.5milligrams once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment. This drug should not be administered to patients with severe hepatic impairment. Older adults (65 years and older) In general, treatment should be initiated at a low dose. When adjusting the dose, the patient's renal or cardiac function and comorbidities should be taken into consideration. Blood pressure should be monitored closely and more frequently in older adults. As there is very limited experience with the use of this drug in older adults aged 75 years and older, very careful monitoring is required when administering this drug.
Child dose
The safety and efficacy of this drug have not been established in pediatric patients under 18 years of age; therefore, its use is not recommended.

Ingredients

Manufacturer
Austin Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with combination therapy

  • Essential hypertension
View approved original text

This combination therapy of amlodipine and olmesartan medoxomil is used in patients whose blood pressure is hard to control due to essential hypertension. These medications work together to dilate blood vessels and lower blood pressure, helping to control blood pressure and reduce the risk of complications. It is effectively used for essential hypertension, resulting in stable blood pressure improvement.

How to take

Adult dose

Take 1 tablet once daily with water, with or without food. If possible, it is recommended that you take it at the same time each day (e.g., in the morning). Before starting this drug, it is recommended that the dose be adjusted using the individual components (olmesartan medoxomil and amlodipine as monotherapy or combination therapy). However, if blood pressure is not controlled with combination therapy of amlodipine and olmesartan medoxomil, switching directly to this drug may be considered as follows. The maximum dose of this drug is 10/40/25mg of amlodipine/olmesartan medoxomil/hydrochlorothiazide. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of 2 weeks or more, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/20mg. - 5/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/40mg or with this drug 5/20/12.5mg. - 5/40/25mg: For patients whose blood pressure is not adequately controlled with this drug 5/40/12.5mg. - 10/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 10/40mg or with this drug 5/40/12.5mg. - 10/40/25mg: For patients whose blood pressure is not adequately controlled with this drug 5/40/25mg or this drug 10/40/12.5mg. ※ Refer to the following dose titration schedule. (The content of each component is listed in the order of amlodipine/olmesartan medoxomil/hydrochlorothiazide.) 5/20/0mg → 5/20/12.5mg ↓ 5/40/0mg → 5/40/12.5mg → 5/40/25mg ↓ ↓ 10/40/0mg → 10/40/12.5mg → 10/40/25mg Patients with renal impairment For patients with mild or moderate renal impairment (creatinine clearance 30-60mL/min), the maximum dose of this drug is 20/5/12.5milligrams once daily. In patients with moderate renal impairment, monitoring of potassium and creatinine levels is recommended. This drug should not be administered to patients with severe renal impairment (creatinine clearance < 30mL/min). Patients with hepatic impairment Caution should be exercised when administering this drug to patients with mild or moderate hepatic impairment. For patients with moderate hepatic impairment, the maximum dose of this drug is 5/20/12.5milligrams once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment. This drug should not be administered to patients with severe hepatic impairment. Older adults (65 years and older) In general, treatment should be initiated at a low dose. When adjusting the dose, the patient's renal or cardiac function and comorbidities should be taken into consideration. Blood pressure should be monitored closely and more frequently in older adults. As there is very limited experience with the use of this drug in older adults aged 75 years and older, very careful monitoring is required when administering this drug.

Child dose

The safety and efficacy of this drug have not been established in pediatric patients under 18 years of age; therefore, its use is not recommended.

Precautions

This medication can cause serious harm to the fetus and newborn during the second and third trimesters of pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. Patients allergic to any components of this medication or related drugs, pregnant or breastfeeding women, patients with severe hypotension, and those with significant cardiac, renal, or liver problems should not take this medication. Patients with low blood volume or salt deficiency may experience hypotension upon initial dosing, so caution is necessary; such cases should start treatment while closely monitoring the condition. This medication can affect renal function, so patients with compromised renal function should have regular blood tests to monitor their condition. Patients with impaired liver function or specific heart diseases should also exercise caution when taking this medication. This drug may interact with other antihypertensive drugs, certain diuretics, lithium, and non-steroidal anti-inflammatory drugs (NSAIDs), so if any other medications are being taken, it is essential to consult a doctor or pharmacist. Side effects such as dizziness or drowsiness may occur during treatment, so driving or operating dangerous machinery should be avoided. Prolonged use of this medication may lead to electrolyte imbalance, hence regular blood tests should be conducted to monitor electrolyte status. Skin may become sensitive to sunlight, so precautions for UV protection should be taken when going outdoors. This medication is not recommended for children under 18 years of age as its safety and efficacy have not been established. In the elderly, the drug's effects and side effects may vary due to decreased renal or liver function, so they should start at a lower dose and take it cautiously. In case of overdose, severe hypotension or heart side effects may occur, and immediate medical attention should be sought for appropriate treatment. Store this medication out of the reach of children, and keep it in a place away from moisture, heat, and direct sunlight.

Side effects

Peripheral edema, headache, dizziness, upper respiratory infection, nasopharyngitis, urinary tract infection, sialadenitis, leukopenia, thrombocytopenia, bone marrow suppression, neutropenia, agranulocytosis, hemolytic anemia, aplastic anemia, anaphylactic reaction, drug hypersensitivity, hyperkalemia, hypokalemia, anorexia, diabetes, hypercalcemia, hyperglycemia, hypomagnesemia, hyponatremia, hypochloremia, hypertriglyceridemia, hypercholesterolemia, hyperuricemia, hypochloremic alkalosis, hyperamylasemia, confusion, depression, apathy, hypersensitivity, anxiety, mood changes, sleep disorders, neurological abnormalities, orthostatic dizziness, syncope, taste disorders, hypertonia, sensory loss, paresthesia, peripheral neuropathy, drowsiness, fainting, seizures, loss of appetite, tremors, visual disturbances, decreased tear production, worsening of myopia, jaundice, vertigo, tinnitus, palpitations, tachycardia, myocardial infarction, arrhythmias, angina, hypotension, flushing, orthostatic hypotension, vasculitis, thrombosis, embolism, cough, bronchitis, dyspnea, pharyngitis, rhinitis, acute aspiration pneumonia, respiratory distress syndrome, pulmonary edema, diarrhea, nausea, constipation, dry mouth, abdominal pain, changes in bowel habits, distension, dyspepsia, gastritis, gastric discomfort, gastroenteritis, gingival hyperplasia, paralytic ileus, pancreatitis, vomiting, hepatitis, jaundice, acute cholecystitis, autoimmune hepatitis, hair loss, angioedema, allergic dermatitis, erythema multiforme, erythema, skin lupus erythematosus-like reaction, pustular rash, exfoliative dermatitis, hyperhidrosis, photosensitivity reactions, pruritus, purpura, Quincke's edema, rash, recurrence of skin lupus erythematosus, toxic skin necrosis, Stevens-Johnson syndrome, urticaria, muscle spasms, joint swelling, muscle weakness, ankle swelling, arthralgia, arthritis, low back pain, paresis, myalgia, bone pain, polyuria, acute renal failure, hematuria, dysuria, nocturia, interstitial nephritis, renal failure, erectile dysfunction, gynecomastia, asthenia, fatigue, chest pain, fever, influenza-like symptoms, lethargy, apathy, edema, pain, facial edema, increased serum creatinine, elevated blood urea, elevated serum uric acid, decreased serum potassium, elevated gamma-glutamyl transferase, elevated alanine aminotransferase, elevated aspartate aminotransferase, elevated liver enzymes, increased serum creatine phosphokinase, weight loss, weight gain, rhabdomyolysis, chronic malabsorption syndrome, drug hypersensitivity, epigastric pain, reduced libido, anasarca, lethargy, altered consciousness, eczema, limb pain, mild decrease in average hemoglobin and hematocrit levels, acute respiratory distress syndrome (ARDS)

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly sealed container to prevent exposure to air or moisture. It is important to maintain the storage temperature between 1 and 30 degrees Celsius to preserve the drug's effectiveness.

Appearance and packaging

Appearance

Pale yellow round film-coated tablet

Package unit

30 tablets/box [10 tablets/Alu-Alu × 3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.